Overall Survival Win for Osimertinib-Chemotherapy in First-Line EGFR-Mutated NSCLC

(MedPage Today) — First-line osimertinib (Tagrisso) plus chemotherapy significantly improved survival versus osimertinib monotherapy in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC).
Among a total of 557 patients, and…

Source link : https://www.medpagetoday.com/meetingcoverage/iaslc/117347

Author :

Publish date : 2025-09-08 00:32:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

Overall Survival Win for Osimertinib-Chemotherapy in First-Line EGFR-Mutated NSCLC

First-Line Osimertinib Plus Chemo Extends Survival in NSCLC

Malnutrition and Infection Rates Increase Before IBD Surgery

Related Posts

The Patient Portal That Patients Can’t Navigate

Can Anticoagulants Cut Stroke Risk in Seniors With AF?

Cognition Improved With Some Drugs for Depression

Why Do Caregivers Delay Early Allergenic Food Introduction?

Which Burnout Programs Work Best for Health Professionals?

‘Lean Diabetes’ a Risk Factor for Dementia?

The Patient Portal That Patients Can’t Navigate

Can Anticoagulants Cut Stroke Risk in Seniors With AF?

Cognition Improved With Some Drugs for Depression

Why Do Caregivers Delay Early Allergenic Food Introduction?

Which Burnout Programs Work Best for Health Professionals?

‘Lean Diabetes’ a Risk Factor for Dementia?

The private notes and secret documents that tell the inside story of the UK’s Covid response

‘California Sober’ Trend Gets a Little Support From Trial

Categories

Archives